



ISPOR Russia HTA Chapter Annual Report 2014

TO:

Board of Directors

International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd. South

PREPARED BY:

Vitaly Omelyanovskiy, MD, PhD, DSC, Professor

Director of the Center for Health Technology Assessment of the
Russian Presidential Academy of National Economy and Public Administration

ISPOR Russia HTA Chapter

Moscow, Russia

Tel: (+7-916-442-4139)

E-mail: vvo@hta-rus.ru, gkh@hta-rus.ru

Background:

The ISPOR Russia HTA Chapter was approved in April 2011. The chapter has 220 members.

The current leadership of the ISPOR Russia HTA Chapter is comprised of the following:

President – Vitaly Omelyanovskiy, MD, PhD, DSC, Professor

Director of the Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration

Vice President – Maria Avxentyeva MD, PhD, DSC, Professor

Deputy Director of the Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration

Executive Director – George Khachatryan, MD, research officer of the Russian Presidential Academy of National Economy and Public Administration

For more information on the ISPOR Russia HTA Chapter, please visit the ISPOR Regional Chapter website:

<http://www.ispor.org/RegionalChapters/Chapter/Russia-HTA>

Enclosure: ISPOR Russia HTA Chapter Annual Report 2014.

ISPOR Russia HTA Chapter Annual Report

The ISPOR Russia HTA Chapter has successfully developed or facilitated the following activities:

SCIENTIFIC/EDUCATIONAL ACTIVITIES:

1. Publications:

The Chapter members published 35 scientific articles in professional journals:

1. Rebrova O. Once Again, on the Quality of Statistical Analysis in Medical Publications: Current Status of the Problem, Recommendations, Peer Reviewing. Medical Technologies: assessment and choice, 2014, №1(15), pp. 8-10.
2. Djalalov S., Djalalova D., Hoch J. Clinical Decision Making: Principles of Building a Decision Tree. Medical Technologies: assessment and choice, 2014, №1(15), pp. 29-36.

3. Maximova L., Omelyanovsky V., Sura M. An Analysis of the Health Care System of the Leading Countries. *Medical Technologies: assessment and choice*, 2014, №1(15), pp. 37-45.
4. Fedyaev D., Maximova L., Omelyanovsky V. Funding Innovative Health Care Technologies with Risk-Sharing Agreements. *Medical Technologies: assessment and choice*, 2014, №1(15), pp. 57-64.
5. Rebrova O., Dobrova N. Clinical and Economic Analysis of Oral Formulations Tegafur (Ftorafur) and Capecitabine (Xeloda) for Colorectal Cancer. *Medical Technologies: assessment and choice*, 2014, №1(15), pp. 72-80.
6. Sapozhnikova I., Tarlowskaya E., Avxentyeva M. Analysis of Clinical Efficacy and Efficiency of Diabetes Mellitus Therapy in Common Practice. *Medical Technologies: assessment and choice*, 2014, №1(15), pp. 81-87.
7. Opimakh I. The Magic Bullet, or the Birth of Chemotherapy. *Medical Technologies: assessment and choice*, 2014, №1(15), pp. 88-92.
8. Rebrova O., Dombrovsky V. On the Registration of Clinical Trials Conducted in the Russian Federation and Publication of Their Results. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 8-10.
9. Djalalov S., Djalalova D., Hoch J. Model Conceptualization in Health Technology Assessment. *Medical Technologies: assessment and choice*, 2014, 2(16), pp. 16-22.
10. Omelyanovsky V. Early Health Technology Assessment as a Tool for Evaluating and Steering the Creation of New Medical Products. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 23-29.
11. Fedyaeva V., Omelyanovsky V., Rebrova O. Multi-Criteria Decision Analysis as a Tool to Support Decision Making: a Review of its Methods and Their Applicability to Health Technology Assessment. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 30-35.
12. Maksimova L., Omelyanovskiy V., Avxentyeva M. Recent Achievements of the European Project EUnetHTA. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 36-41.
13. Sura M., Avxentyeva M., Omelyanovsky V., Fedyaev D., Andreyeva N., Zateyschikov D., Fofanova T. Clinical and Economic Grounds for Implementing a System of Outpatient Provision of Medications to Working-Age Hypertensive Patients in the Russian Federation. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 42-54.
14. Pyadushkina E., Ignatyeva V., Omelyanovsky V. Comparative Clinical and Economic Analysis of the Use of Nucleoside Reverse Transcriptase Inhibitor in the Form of Fixed Dose Combination with the Patients Who Have No Experience in Anti-Retroviral Therapy of AIDS. *Medical Technologies: assessment and choice*, 2014, №2(16), pp. 66-72.
15. Djalalov S., Djalalova D., Hoch J. Introduction to Economic Evaluation of Health Technologies. *Medical Technologies: assessment and choice*, 2014, №3(17), pp. 10-17.
16. Fedyaev D., Maximova L., Omelyanovsky V. The Role of Health Technology Assessment, Reimbursement and Pricing Systems in Risk-Sharing Agreements. *Medical Technologies: assessment and choice*, 2014, №3(17), pp. 25-31.
17. Sura M., Omelyanovsky V., Avksentyeva M., Tatarinov A., Gerasimova K. Analysis of Amount and Volume of Financing Patients with Orphan Diseases in the Russian Federation. *Medical Technologies: assessment and choice*, 2014, №3(17), pp. 43-50.
18. Opimakh I. Passion for Insulin. *Medical Technologies: assessment and choice*, 2014, №3(17), pp. 58-62.
19. Omelyanovskiy V., Maksimova L., Tatarinov A. Parameters of health care systems. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №2, pp. 51-56.
20. Ignatyeva V., Avxentyeva M. The Analysis of methodologic characteristics of researches on social and economic burden of diseases in russia in the frames of development of standard cost of illness methodology for the health technology assessment. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №3, pp. 3-11.
21. Ignatyeva V., Avxentyeva M., Omelyanovsky V., Khachatryan G.R. Modeling clinical and economic outcomes of testing for LTBI with T-SPOT.TB in immunocompromised children. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №3, pp. 12-19.

22. Dombrovskiy V., Omelyanovskiy V. Problems of outcomes choice for the assessment of rehabilitation programs efficiency in patients after stroke and craniocerebral injury. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №3, pp. 20-25.
23. Fedyaev D., Fedyaeva V., Omelyanovsky V. Economic justification for telehealth technology use for preventive medical examination of the population in remote regions. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №3, pp. 30-35.
24. Sura M., Gerasimova K., Omelyanovskiy V., Avksentyeva M. Assessment of necessary financial expenses on the drug supply of the patients with orphan diseases in the Russian Federation. *Pharmacoeconomics. The Actual Pharmacoeconomics and Pharmacoepidemiology*, 2014, №3, pp. 36-43.
25. Khachatryan G., Gostishchev R. Clinical investigations of innovative technologies of pancreatic cancer treatment. *Surgery named after N.I. Pirogov*, 2014, №11, pp. 73-80.
26. Dombrovskiy V., Rakina E., Rebrova O. Assessment of the methodological quality of randomized controlled trials published in «Russian Allergology Journal» in 2009–2013 (part 1). *Russian Allergology Journal*, 2014 №3, pp. 53-62.
27. Omelyanovskiy V., Maksimova L., Tatarinov. A. International experience: financial models and healthcare system organization. *Financial Journal*, 2014, №3, pp. 22-34.
28. Ignatieva V. Assessment of social and economic burden of cancer of four localizations with standardized methodology. *Problems of standardization in healthcare*, 2014, №7-8, pp. 58-65.
29. Ignatyeva V., Derkach E., Avxentyeva M., Omelyanovsky V. The cost of melanoma and kidney, prostate, and ovarian cancers in Russia. *Value in Health Regional Issues*, 2014, №4, pp. 15-22.
30. Rebrova O., Rakina E. Evidence-based medicine: implementation in Russian healthcare. *Evidence-based medicine*, 2014, №7, pp. 62-67.
31. Avxentyeva M., Pyadushkina E., Derkach E. Economic evaluation of various strategies for antiviral therapy for previously treated patients with chronic HCV genotype 1 infection. *Value in Health*, vol. 17, issue 6, pp. A365-A365.
32. Pyadushkina E., Avxentyeva M., Omelyanovsky V., Treur M., Westerhout K. Cost-effectiveness analysis of antiviral pharmacotherapies for treatment of chronic hepatitis C virus infection in Russia. *Value in Health*, vol. 17, issue 6, pp. A366-A367.
33. Ignatyeva V., Pyadushkina E., Omelyanovsky V. Fixed dose combinations of nucleoside transcriptase inhibitor for naïve patient with HIV infection in Russia: cost comparison. *Value in Health*, vol. 17, issue 6, p. A669.
34. Ignatyeva V., Avxentyeva M., Galstyan G., Bregovskiy V., Udovichenko O. Direct Costs of Diabetic Foot Ulcers in Russia. *Value in Health*, vol. 17, issue 7, p. A342.
35. Ignatyeva V., Avxentyeva M., Galstyan G., Bregovskiy V., Udovichenko O. Cost-Effectiveness of Interventions Aimed at Decreasing The Number of Amputations Among Patients With Diabetes Mellitus. *Value in Health*, vol. 17, issue 7, p. A346.

2. Seminars and trainings:

Together with Market Access Consulting the Chapter conducted 10 trainings in different regions of Russia covering such topics as financing the Russian healthcare system, economical effectiveness of new medical technologies, drug supply under the new contract system, DRG in Russian healthcare, regional market access and GR in healthcare.

3. Presentations and Participation in Round tables/Special Sessions at Major Medical Conferences and Congresses and Market Access events:

ISPOR Russia HTA Chapter members made about 70 presentations at more than 40 major domestic and international health conferences and congresses in Russia and abroad, including:

- ISPOR 19th Annual International Congress in Montreal, Canada, May 31 – June 4;
- ISPOR 17th Annual European Congress in Amsterdam, the Netherlands, November 8-12;
- 4th Pharmaceutical Pricing and Reimbursement Forum, Frankfurt, Germany, January 29-30;

- The 21st National Congress «Man and drug», Moscow, April 6-10;
- The 8th Scientific Congress «Rational Pharmacotherapy», St. Petersburg, October 16-18;
- The 9th Annual Congress of Specialists in Perinatal medicine, Moscow, September 22-23;
- The 5th Forum of Innovative Technologies «Info Space», Moscow, March 25-26;
- International Forum Europe and Russia. Development vector: harmonization (4th Session), Moscow, 2nd December;
- The 18th Russian Oncologic Congress, Moscow, November 11-13;
- Conference «The Moscow Time conferences», Moscow, September 23th;
- 3rd Annual Autumn Forum «FarmAccess», Berlin, Germany, October 8th.

4. Pharmacoeconomic studies:

ISPOR Russia HTA Chapter completed 10 pharmacoeconomic and health economics studies covering multiple therapeutic areas, compounds and indications.

5. Research & Development projects:

ISPOR Russia HTA Chapter completed 4 Research & Development projects covering such topics as development of approaches for payment of new costly technologies based on risk-sharing agreements, development of methodology of HTA in Russian Federation (including economical evaluation of effectiveness of patient rehabilitation programs after traumatic brain injury and acute cerebrovascular events), creation of methodology of developing pricing regulation system on drugs funded from healthcare system and development of risk-sharing model of compulsory health insurance in Russia.

6. Development of HTA approaches:

ISPOR Russia HTA Chapter published following methodological guidances and informational bulletins:

- **Methodological Guidance on Application of Multi Criteria Decision Making Analysis in Russian Healthcare**

ISPOR Russia HTA Chapter together with the Expert Board on Healthcare of the Federation Council's Committee on Social Policy and the Scientific and Research Financial Institute of the Ministry of Finance of the Russian Federation has just published a Methodological Guidance on Application of Multi Criteria Decision Making Analysis in Russian Healthcare. This brochure clarifies many complicated aspects of MCDA, identifies the roles of different interested groups (patients, doctors, experts in health economics, payers, administrators and politicians), provides an instrument of decision making under concrete circumstances of the Russian healthcare system.

- **Information bulletin «Analysis of needed financial expenses for pharmaceutical supply of patients with orphan diseases in Russia»**

The research was carried out by the Center for Health Technology Assessment (HTA) of the Russian Presidential Academy of National Economy and Public Administration (RANEPA) in cooperation with the Expert Board on Healthcare of the Social Policy Committee of the Federation Council and with the Center for Healthcare Funding of the Financial Scientific Research Institute at the Ministry of Finance of Russia. The aim of the study was to determine amount of needed financial expenses for pharmaceutical supply of the Russian patients with orphan diseases.

7. ISPOR Russia HTA Chapter members actively participated in the ISPOR 17th European Congress on 8-12 November 2014 in Amsterdam, The Netherlands, with the following 9 poster presentations:

1) PHARMACOECONOMIC ANALYSIS OF ORAL CAPECITABINE AND TEGAFUR FOR COLORECTAL CANCER TREATMENT IN RUSSIA

Gerasimova K., Avxentyeva M., Aksenov V., Rebrova O., Dobrova N.

2) EFFICIENCY OF REHABILITATION PROGRAMS FOR PATIENTS AFTER TRAUMATIC BRAIN INJURY AND ACUTE CEREBROVASCULAR ACCIDENT (STROKE) IN RUSSIA

Omelyanovskiy V., Avxentyeva M., Derkach E., **Dombrovskiy V.**, Fedyaev D.

3) DIRECT COSTS OF DIABETIC FOOT ULCERS IN RUSSIA

Ignatyeva V., Avxentyeva M., Galstyan G., Bregovskiy V., Udovichenko O.

4) COST-EFFECTIVENESS OF INTERVENTIONS AIMED AT DECREASING THE NUMBER OF AMPUTATIONS AMONG PATIENTS WITH DIABETES MELLITUS

Ignatyeva V., Avxentyeva M., Galstyan G., Bregovskiy V., Udovichenko O.

5) FIXED DOSE COMBINATIONS OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR NAÏVE PATIENT WITH HIV INFECTION IN RUSSIA: COST COMPARISON ANALYSIS

Ignatyeva V., Pyadushkina E., Omelyanovskiy V.

6) ASSESSMENT OF THE METHODOLOGICAL QUALITY OF RANDOMIZED CONTROLLED TRIALS PUBLISHED IN "RUSSIAN ALLERGOLOGY JOURNAL" IN 2009-2013

Dombrovskiy V., **Rakina E.**, Rebrova O.

7) ECONOMIC EVALUATION OF THE USE OF AN INFANT FORMULA BASED ON PARTIALLY HYDROLYZED SERUM PROTEIN AS COMPARED WITH A STANDARD WHOLE COW'S MILK FORMULA FOR PREVENTION OF ATOPIC DERMATITIS IN CHILDREN UNDER 3 YEARS OLD

Derkach E., Avxentyeva M., Fedyaeva V., Rebrova O.

8) ESTIMATING THE COSTS OF DRUG SUPPLY FOR RARE DISEASES PATIENTS IN RUSSIA

Sura M., **Gerasimova K.**, Omelyanovskiy V., Avxentyeva M., Tatarinov A., Fedyaev D.

9) MCDA APPROACH TO RANKING RARE DISEASES IN RUSSIA: PRELIMINARY RESULTS

Fedyaeva V., Omelyanovskiy V., Rebrova O., Khan N., Petrovskaya E.

8. Participation in ISPOR short courses:

ISPOR Russia HTA Chapter members participated in 3 different short courses organized within the framework of the 17th ISPOR Annual European ISPOR Congress on 8-12 November 2013 in Amsterdam, The Netherlands.

POLICY-RELATED ACTIVITIES:

- ISPOR Russia HTA Chapter supported the amendment to Russian federal law №61 an article on HTA and creating a state body of HTA in Russian Federation in the following;
- ISPOR Russia HTA Chapter organized 3 meetings on creation and support of Regional HTA body in Samara oblast;

- Together with the Council of Federation ISPOR Russia HTA Chapter organized 18 meetings on different aspects of HTA in a number of important therapeutic areas, including 11 meetings in Moscow (including several high level meeting on introducing HTA in Russia with the Speaker of the Russian Federation, the Vice Speaker of the State Duma, Minister of Health and Minister of Finance) and 7 meetings in various Russian regions (St. Petersburg, Tyumen oblast, the Republic of Bashkortostan, Samara oblast, the Republic of Tatarstan, the Republic of Dagestan).

CHAPTER MEETINGS and WORKSHOPS:

ISPOR Russia HTA Chapter President Omelyanovskiy V. and Vice President Avxentyeva M. made presentations at CEE Network Forum «The Policy Challenges of Rare Diseases in CEE Region» and ISPOR Russia HTA Chapter President Omelyanovskiy V. made presentation at CEE Education Committee Meeting at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

ISPOR Russia organized Conjoint ISPOR Russia HTA and ISPOR St. Petersburg Chapters Meeting, November 11, 2014, at the 17th Annual European Congress in Amsterdam, The Netherlands, November 8-12, 2014.

MEMBERSHIP DEVELOPMENT:

ISPOR Russia HTA Chapter has added 15 members since the end of 2013. The total number of Chapter members is over 200.

Upcoming Activities for ISPOR Russia HTA Chapter in 2015

Tentative Agenda

Date	Activities
January-December	Development of MCDA methodology for orphan drugs assessment
February-October	Lobbying amendment in Russian federal law №323 on comprehensive HTA
February-December	Developing IT-based algorithms of conducting evidence-based analysis
March	Internal chapter meetings, Moscow
April	Training on advancement of drugs in DRG system
May	Participating in meetings within the framework of the ISPOR 20th Annual International Congress in Philadelphia, USA
May-June	Trainings covering such topics as financing Russian healthcare system, advancement of oncologic drugs in DRG system, market access and GR in healthcare
July-December	Cooperation with the stakeholders and GR on creation of HTA body in Russia
September	Conference on HTA, Moscow, Russia
November	Participating in meetings within the framework of the ISPOR 18th Annual European Congress in Milan, Italy
November-December	Training on regional strategy of advancement of drugs under current conditions

